CellVoyant—an artificial intelligence (AI) first biotechnology company spun out of the University of Bristol—has raised £7.6 million in seed funding to speed up the development of novel cell therapies. According to a Jan. 16, 2024 press release, the funding was led by Octopus Ventures and included Horizon Ventures, Verve Ventures, and Air Street Capital as participants of the funding round. Source: Biopharm International 16/1/2024